Zhang Jiayi, Zhang Mingxi, Liu Xiaorui, Jia Zehua, Zhang Jingxing, Tang Yunhua, Wang Tielong, He Xiaoshun
Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Guangdong Provincial Key Laboratory of Organ Medicine, Guangzhou, 510080, China.
World J Surg Oncol. 2025 Jul 31;23(1):308. doi: 10.1186/s12957-025-03919-7.
Liver transplantation (LT) is the main treatment for HCC patients, but postoperative complications such as early allograft dysfunction (EAD), acute rejection (AR), and biliary complications can affect the prognosis of patients. However, whether the occurrence of early complications after transplantation will affect the overall survival and tumor recurrence of patients have not been fully studied. We conducted a retrospective clinical study to evaluate the impact of early complications on overall survival and their relationship with HCC recurrence after liver transplantation.
This retrospective study analyzed 378 patients who underwent liver transplantation for HCC between January 2015 and December 2020 at The First Affiliated Hospital, Sun Yat-sen University. The follow-up data of overall survival (OS) and recurrence-free survival (RFS) were collected.
Median recurrence-free survival (RFS) was 92.18 months, with RFS rates of 75.9% at 1 year, 60.8% at 3 year, 56.1% at 5 years. 239 (63.2%) patients remained alive following transplantation, and the median overall survival was 100.75 months, with survival rates of 90.5% at 1 year, 71.2% at 3 year, 66.3% at 5years. Multivariate Cox’s regression analysis revealed that postoperative acute rejection (AR) and postoperative early allograft dysfunction (EAD) were independent risk factors for overall survival (OS). AR was the independent risk factors for recurrence-free survival.
EAD and AR are independent risk factors for overall survival, and AR is an independent risk factor for recurrence-free survival. Reducing the incidence of EAD, AR and biliary complications after transplantation can effectively improve the overall survival and recurrence-free survival of patients.
肝移植(LT)是肝癌患者的主要治疗方法,但术后并发症如早期移植物功能障碍(EAD)、急性排斥反应(AR)和胆道并发症会影响患者的预后。然而,移植后早期并发症的发生是否会影响患者的总生存期和肿瘤复发尚未得到充分研究。我们进行了一项回顾性临床研究,以评估早期并发症对总生存期的影响及其与肝移植后肝癌复发的关系。
这项回顾性研究分析了2015年1月至2020年12月在中山大学附属第一医院接受肝癌肝移植的378例患者。收集了总生存期(OS)和无复发生存期(RFS)的随访数据。
中位无复发生存期(RFS)为92.18个月,1年时RFS率为75.9%,3年时为60.8%,5年时为56.1%。239例(63.2%)患者移植后存活,中位总生存期为100.75个月,1年时生存率为90.5%,3年时为71.2%,5年时为66.3%。多因素Cox回归分析显示,术后急性排斥反应(AR)和术后早期移植物功能障碍(EAD)是总生存期(OS)的独立危险因素。AR是无复发生存期的独立危险因素。
EAD和AR是总生存期的独立危险因素,AR是无复发生存期的独立危险因素。降低移植后EAD、AR和胆道并发症的发生率可有效提高患者的总生存期和无复发生存期。